Clinical Trial Detail

NCT ID NCT02509507
Title Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

clear cell renal cell carcinoma

breast adenocarcinoma

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

gastric squamous cell carcinoma

colorectal adenocarcinoma

melanoma

gastric adenocarcinoma

lung non-small cell carcinoma

Therapies

Pembrolizumab + Talimogene laherparepvec

Talimogene laherparepvec

Age Groups: adult senior

No variant requirements are available.